IRIDEX (NASDAQ:IRIX) Releases Quarterly Earnings Results, Hits Estimates

IRIDEX (NASDAQ:IRIX) issued its quarterly earnings results on Thursday. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05), Zacks reports. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $12.80 million.

IRIDEX Stock Performance

Shares of IRIDEX stock opened at $0.88 on Friday. The firm has a market cap of $14.69 million, a PE ratio of -1.32 and a beta of 0.94. IRIDEX has a 1 year low of $0.78 and a 1 year high of $3.65. The firm’s 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.59. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of IRIDEX in a research report on Tuesday. They set a “hold” rating for the company.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.